Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7243 results

Sort By:

BREAST Choice Decision Tool R21

Study ID: NCT06817226
Start Date: 2024-10-10
End Date: 2025-08
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment

Assess decision making context.

Solicit input from the target population

Integration and refinemen of the decision aid

Sponsor

UNC Lineberger Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Genomic Services Research Program

Study ID: NCT02595957
Start Date: 2014-09-16
End Date: 2028-12-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

5000

Intervention / Treatment
Sponsor

National Human Genome Research Institute (NHGRI)

Source: clinicaltrials.gov

Share:
Add to list

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Study ID: NCT06467357
Start Date: 2024-08-12
End Date: 2029-05-16
Study Type

Interventional

Study Phase

Phase3

No. of Participants

620

Intervention / Treatment

Gemcitabine

Cisplatin

Durvalumab

Trastuzumab deruxtecan

Rilvegostomig

Agilent HercepTest™ mAb pharmDx

Ventana PD-L1 SP263 assay

Sponsor

AstraZeneca

Source: clinicaltrials.gov

Share:
Add to list

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Study ID: NCT05829226
Start Date: 2022-12-12
End Date: 2026-03
Study Type

Interventional

Study Phase

Phase1

No. of Participants

90

Intervention / Treatment

Listen-200

Venetoclax

Azacitidine

Decitabine

Sponsor

Pureech

Source: clinicaltrials.gov

Share:
Add to list

BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Study ID: NCT04752826
Start Date: 2021-01-25
End Date: 2028-01-15
Study Type

Interventional

Study Phase

Phase2

No. of Participants

176

Intervention / Treatment

BI-1808

Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection

Sponsor

BioInvent International AB

Source: clinicaltrials.gov

Share:
Add to list

Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

Study ID: NCT04764357
Start Date: 2021-06-04
End Date: 2027-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment

Paxman Scalp Cooling System

Alopecia Assessments

Patient Reported Outcomes Questionnaires

Sponsor

St. Jude Children's Research Hospital

Source: clinicaltrials.gov

Share:
Add to list

Evaluation of Canakinumab in High-Risk Former-Smokers

Study ID: NCT06038526
Start Date: 2024-03-11
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

75

Intervention / Treatment

Biospecimen Collection

Bronchoscopy

Kankinumab

Carbon Monoxide Measurement

Survey Administration

Sponsor

Peter Shields

Source: clinicaltrials.gov

Share:
Add to list

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

Study ID: NCT04923126
Start Date: 2021-06-21
End Date: 2031-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

132

Intervention / Treatment

Mirdamet

Sponsor

St. Jude Children's Research Hospital

Source: clinicaltrials.gov

Share:
Add to list

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

Study ID: NCT05584826
Start Date: 2022-10-06
End Date: 2025-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

20

Intervention / Treatment

MDMA

Sponsor

Sunstone Medical

Source: clinicaltrials.gov

Share:
Add to list

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Study ID: NCT06324357
Start Date: 2024-06-28
End Date: 2029-09-28
Study Type

Interventional

Study Phase

Phase2

No. of Participants

582

Intervention / Treatment

Zongertinib

Trastuzumab deruxtecan

Trastuzumab emtansine

Trastuzumab

Capecitabine

Sponsor

Boehringer Ingelheim

Source: clinicaltrials.gov

Share:
Add to list